Levi Garraway, Roche CMO (Source: Genentech)

FDA hands out a quick OK for po­ten­tial SMA block­buster ris­diplam, giv­ing Genen­tech and Roche a chance to chal­lenge ri­vals on the price

US reg­u­la­tors hand­ed Roche and Genen­tech a big win Fri­day af­ter­noon, one that has mar­ket-shap­ing po­ten­tial for its high-priced ri­vals from No­var­tis and Bio­gen.

The FDA has green-lit the com­pa­nies’ spinal mus­cu­lar at­ro­phy drug ris­diplam, which will be mar­ket­ed as Evrys­di in the US, for use in pa­tients two months and old­er. It’s the first SMA drug that can be tak­en oral­ly, as Bio­gen’s Spin­raza is in­ject­ed in­to the spine while No­var­tis’ Zol­gens­ma is a gene ther­a­py.

An­a­lysts have pen­ciled in a peak sales es­ti­mate of around $2 bil­lion for this drug.

“Evrys­di, with its at-home de­liv­ery made pos­si­ble by oral dos­ing, rep­re­sents an im­por­tant and time­ly ad­vance­ment for peo­ple with SMA,” said Genen­tech CMO Levi Gar­raway in a state­ment emailed to End­points News. “Dur­ing these chal­leng­ing times, we are ex­treme­ly proud to bring this ground­break­ing med­i­cine to those liv­ing with this high­ly dis­abling, rare neu­ro­log­i­cal con­di­tion.”

Ris­diplam will be mar­ket­ed in the US by Genen­tech and glob­al­ly by Roche should it at­tain fur­ther ap­provals. The biotech de­vel­oped ris­diplam with the SMA Foun­da­tion and part­ner PTC Ther­a­peu­tics.

Fri­day’s an­nounce­ment came ahead of sched­ule, as the PDU­FA date on ris­diplam had been slat­ed for Au­gust 24.

Bill An­der­son

As for the cost, Evrys­di is priced sig­nif­i­cant­ly low­er than its SMA com­peti­tors. The price max­es out at $340,000 an­nu­al­ly, a Genen­tech spokesper­son told End­points News, and is scaled on a pa­tient’s weight. The cost for an in­fant weigh­ing 15 pounds who is less than two years old would be un­der $100,000, the spokesper­son added.

The pric­ing scale caps when the child reach­es 44 pounds, which puts the av­er­age at about $7727.27 per pound per year for every pa­tient.

Roche CEO Bill An­der­son said ear­ly this year that the plan was to “un­der­whelm with our pric­ing” and they seem to have done so, and more. Un­der­whelm­ing didn’t prove very chal­leng­ing — Zol­gens­ma has the du­bi­ous des­ig­na­tion of most ex­pen­sive drug in the world at $2.1 mil­lion per pa­tient, while Spin­raza costs $750,000 for the first year and then $375,000 every sub­se­quent year.

The rea­son­ing be­hind the weight-based scale is due to how in­fants me­tab­o­lize drugs dif­fer­ent­ly than old­er in­di­vid­u­als, PTC CEO Stu­art Peltz told End­points, adding “the strat­e­gy is there’s a large num­ber of pa­tients who are un­treat­ed, and I think Roche’s ex­pec­ta­tion is to get it to the pa­tients as rapid­ly as pos­si­ble.”

Stu­art Peltz

Evrys­di was ap­proved based on two clin­i­cal tri­als that test­ed ef­fi­ca­cy in var­i­ous ages and sever­i­ties, and the FDA hand­ed the drug quite the broad la­bel. Pre­vi­ous­ly on­ly Spin­raza had been ap­proved to treat SMA in adults and Peltz said the de­vel­op­ment teams fo­cused on a broad tri­al pop­u­la­tion in or­der to serve pa­tients that had pre­vi­ous­ly been un­der­rep­re­sent­ed. No ap­proved treat­ments for SMA ex­ist­ed be­fore 2016.

The Covid-19 pan­dem­ic has al­so thrown a wrin­kle in­to Evrys­di’s launch giv­en the drug’s ease of use at home. While the oth­er ther­a­pies in­volve go­ing out to re­ceive in­jec­tions, Evrys­di is a liq­uid in­gest­ed once a day oral­ly and Peltz said he be­lieves this ac­ces­si­bil­i­ty will make the drug more prefer­able for those still too ner­vous to ven­ture out­doors fre­quent­ly.

Baird an­a­lyst Bri­an Sko­r­ney large­ly agreed with that as­sess­ment, writ­ing to in­vestors, “With the fear of COVID on every­one’s mind, we think it puts Evrys­di in a mar­ketable ad­van­tage over Spin­raza.” That, com­bined with Evrys­di’s sig­nif­i­cant­ly low­er cost, re­sults in the drug “putting sig­nif­i­cant com­pet­i­tive pres­sure” on Spin­raza, which gar­nered $2.1 bil­lion in 2019.

Biotech Half­time Re­port: Af­ter a bumpy year, is biotech ready to re­bound?

The biotech sector has come down firmly from the highs of February as negative sentiment takes hold. The sector had a major boost of optimism from the success of the COVID-19 vaccines, making investors keenly aware of the potential of biopharma R&D engines. But from early this year, clinical trial, regulatory and access setbacks have reminded investors of the sector’s inherent risks.

RBC Capital Markets recently surveyed investors to take the temperature of the market, a mix of specialists/generalists and long-only/ long-short investment strategies. Heading into the second half of the year, investors mostly see the sector as undervalued (49%), a large change from the first half of the year when only 20% rated it as undervalued. Around 41% of investors now believe that biotech will underperform the S&P500 in the second half of 2021. Despite that view, 54% plan to maintain their position in the market and 41% still plan to increase their holdings.

How to col­lect and sub­mit RWD to win ap­proval for a new drug in­di­ca­tion: FDA spells it out in a long-await­ed guid­ance

Real-world data is messy. There can be differences in the standards used to collect different types of data, differences in terminologies and curation strategies, and even in the way data is exchanged.

While acknowledging this somewhat controlled chaos, the FDA is now explaining how biopharma companies can submit study data derived from real-world data (RWD) sources in applicable regulatory submissions, including new drug indications.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

David Livingston (Credit: Michael Sazel for CeMM)

Renowned Dana-Far­ber sci­en­tist, men­tor and bio­phar­ma ad­vi­sor David Liv­ingston has died

David Livingston, the Dana-Farber/Harvard Med scientist who helped shine a light on some of the key molecular drivers of breast and ovarian cancer, died unexpectedly last Sunday.

One of the senior leaders at Dana-Farber during his nearly half century of work there, Livingston was credited with shedding light on the genes that regulate cell growth, with insights into inherited BRCA1 and BRCA2 mutations that helped lay the scientific foundation for targeted therapies and earlier detection that have transformed the field.

Sen. Richard Durbin (D-IL, foreground) and Sen. Richard Blumenthal (D-CT) (Patrick Semansky/AP Images)

Sen­a­tors back FDA's plan to re­quire manda­to­ry pre­scriber ed­u­ca­tion for opi­oids

Three Senate Democrats are backing an FDA plan to require mandatory prescriber education for opioids as overdose deaths have risen sharply over the past decade, with almost 97,000 American opioid-related overdose deaths in the past year alone.

While acknowledging a decline in overall opioid analgesic dispensing in recent years, the FDA said it’s reconsidering the need for mandatory prescriber training through a REMS given the current situation with overdoses, and is seeking input on the aspects of the opioid crisis that mandatory training could potentially mitigate.

David Lockhart, ReCode Therapeutics CEO

Pfiz­er throws its weight be­hind LNP play­er eye­ing mR­NA treat­ments for CF, PCD

David Lockhart did not see the meteoric rise of messenger RNA and lipid nanoparticles coming.

Thanks to the worldwide fight against Covid-19, mRNA — the genetic code that can be engineered to turn the body into a mini protein factory — and LNPs, those tiny bubbles of fat carrying those instructions, have found their way into hundreds of millions of people. Within the biotech world, pioneers like Alnylam and Intellia have demonstrated just how versatile LNPs can be as a delivery vehicle for anything from siRNA to CRISPR/Cas9.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,300+ biopharma pros reading Endpoints daily — and it's free.

Leen Kawas (L) has resigned as CEO of Athira and will be replaced by COO Mark Litton

Ex­clu­sive: Athi­ra CEO Leen Kawas re­signs af­ter in­ves­ti­ga­tion finds she ma­nip­u­lat­ed da­ta

Leen Kawas, CEO and founder of the Alzheimer’s upstart Athira Pharma, has resigned after an internal investigation found she altered images in her doctoral thesis and four other papers that were foundational to establishing the company.

Mark Litton, the company’s COO since June 2019 and a longtime biotech executive, has been named full-time CEO. Kawas, meanwhile, will no longer have ties to the company except for owning a few hundred thousand shares.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bris­tol My­ers pledges to sell its Ac­celeron shares as ac­tivist in­vestors cir­cle Mer­ck­'s $11.5B buy­out — re­port

Just as Avoro Capital’s campaign to derail Merck’s proposed $11.5 billion buyout of Acceleron gains steam, Bristol Myers Squibb is leaning in with some hefty counterweight.

The pharma giant is planning to tender its Acceleron shares, Bloomberg reported, which add up to a sizable 11.5% stake. Based on the offer price, the sale would net Bristol Myers around $1.3 billion.

To complete its deal, Merck needs a majority of shareholders to agree to sell their shares.

Boost­er bo­nan­za: FDA en­dors­es 'mix-and-match' scheme, and Mod­er­na and J&J too

The FDA late Wednesday signed off on authorizing the use of heterologous — or what FDA calls a “mix and match” of a primary vaccine series and different booster doses — for all currently available Covid-19 vaccines, in addition to separately authorizing Moderna and J&J boosters.

On the mix-and-match approach, which FDA officials insisted isn’t too confusing in a press conference, the agency offered the example of an 18-year-old who received the J&J shot at least two months ago and may now receive a single booster of the J&J, a half dose of the Moderna, or the Pfizer-BioNTech booster.

No­vo CEO Lars Fruer­gaard Jør­gensen on R&D risk, the deal strat­e­gy and tar­gets for gen­der di­ver­si­ty

 

I kicked off our European R&D summit last week with a conversation involving Novo Nordisk CEO Lars Fruergaard Jørgensen. Novo is aiming to launch a new era of obesity management with a new approval for semaglutide. And Jørgensen had a lot to say about what comes next in R&D, how they manage risk and gender diversity targets at the trendsetting European pharma giant.

John Carroll: I’m here with Lars Jørgensen, the CEO of Novo Nordisk. Lars, it’s been a really interesting year so far with Novo Nordisk, right? You’ve projected a new era of growing sales. You’ve been able to expand on the GLP-1 franchise that was already well established in diabetes now going into obesity. And I think a tremendous number of people are really interested in how that’s working out. You have forecast a growing amount of sales. We don’t know specifically how that might play out. I know a lot of the analysts have different ideas, how those numbers might play out, but that we are in fact embarking on a new era for Novo Nordisk in terms of what the company’s capable of doing and what it’s able to do and what it wants to do. And I wanted to start off by asking you about obesity in particular. Semaglutide has been approved in the United States for obesity. It’s an area of R&D that’s been very troubled for decades. There have been weight loss drugs that have come along. They’ve attracted a lot of attention, but they haven’t actually ever gained traction in the market. My first question is what’s different this time about obesity? What is different about this drug and why do you expect it to work now whereas previous drugs haven’t?

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.